Nicolau DP, et al. – An alternative therapy in development, ultrasonic drug dispersion (UDD), uses a subcutaneous injection followed by external transcutaneous ultrasound to deliver high tissue concentrations of cefazolin with limited systemic exposure. While it is postulated that these high concentrations may be suitable to treat more resistant organisms such as methicillin–resistant Staphylococcus aureus (MRSA), here the authors explored the cefazolin minimum inhibitory concentration (MIC) distribution for this organism. Using the novel drug delivery system, the overwhelming majority of MRSA indicated cefazolin MICs considerably lower than achievable tissue concentrations (≥1,000 mg/L). While the currently defined cefazolin MRSA phenotypic profile precludes the use of parenteral administration, techniques that deliver local exposures in excess of these inhibitory concentrations could provide a novel treatment strategy for skin and skin structure infections.